Elite in Mast Cell Activation Syndrome (MCAS)

Karin P. Hartmann

1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Mast Cell Activation Syndrome (MCAS)
1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Karin Hartmann practices in Luebeck, Germany. Ms. Hartmann is rated as an Elite expert by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). Her top areas of expertise are Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Anaphylaxis, and Urticaria Pigmentosa.

Her clinical research consists of co-authoring 196 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 83 articles and participated in 2 clinical trials in the study of Mast Cell Activation Syndrome (MCAS).

Gender
Female

Locations

1Department Of Dermatology, Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Other Locations
Frankfurter Str. 98, Giessen, HE 35392, Germany
Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
Enrollment Status: Completed
Publish Date: September 02, 2025
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3
View 3 Less Clinical Trials

196 Total Publications

Outstanding Issues Need to Be Clarified.
Outstanding Issues Need to Be Clarified.
Journal: Deutsches Arzteblatt international
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hartmann's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile